Transmedics Group, INC 8-K filings

TransMedics Group, Inc. issued additional information clarifying the significant impact of a $103.3 million U.S. tax valuation allowance release on its previously reported fourth-quarter 2025 financial results.

TransMedics Group, Inc. reported robust financial results for the fourth quarter and full year 2025, driven by significant revenue growth and increased adoption of its OCS NOP program.

TransMedics Group, Inc. announced significant leadership transitions, appointing new Chief Commercial Officer and General Counsel while retaining outgoing executives in new capacities.

TransMedics Group, Inc. has entered a major 16-year lease for a new 498,286 sq ft headquarters in Somerville, MA, with options to extend and purchase, signaling significant long-term strategic expansion.

TransMedics Group, Inc. announced robust third-quarter 2025 financial results, including a 32% revenue increase and raised full-year guidance, driven by strong OCS and NOP utilization.

TransMedics Group, Inc. acquired another fixed-wing aircraft for approximately $14.5 million, bringing its total fleet to 22 for its National OCS Program.

TransMedics Group, Inc. announced robust second-quarter 2025 financial results, including a 38% revenue increase and significant net income growth, leading to an upward revision of its full-year 2025 revenue guidance.

TransMedics Group, Inc. announced that its shareholders re-elected all eight director nominees, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as its independent auditor at the 2025 Annual Meeting.

TransMedics announces a 48% increase in first-quarter revenue and raises its full-year revenue guidance, driven by the success of its Organ Care System (OCS) and National OCS Program (NOP).

TransMedics announces impressive financial results for Q4 and full year 2024, highlighted by significant revenue growth and profitability.

TransMedics Group, Inc. finalizes the acquisition of a fixed-wing aircraft for $14.3 million, expanding its fleet to 21 aircraft to support its National OCS Program.

TransMedics Group has finalized the acquisition of its 20th fixed-wing aircraft for approximately $14.1 million, expanding its fleet for the National OCS Program.

TransMedics Group has finalized the acquisition of its 19th fixed-wing aircraft for approximately $13.9 million, expanding its fleet for the National OCS Program.

TransMedics Group, Inc. has appointed Gerardo Hernandez as its new Chief Financial Officer, effective December 2, 2024, and updated its full-year 2024 revenue guidance to $428-$432 million.

TransMedics Group, Inc. announced a 64% increase in revenue for the third quarter of 2024, reaching $108.8 million, and net income of $4.2 million.

TransMedics Group has finalized the acquisition of its 18th fixed-wing aircraft for approximately $14.4 million, expanding its fleet for the National OCS Program.

TransMedics announced a significant 118% increase in revenue for the second quarter of 2024, reaching $114.3 million, and a net income of $12.2 million.

TransMedics Group has completed the acquisition of its 17th fixed-wing aircraft for approximately $14 million, expanding its fleet for the National OCS Program.

TransMedics Group has acquired two additional fixed-wing aircraft for approximately $28.2 million, expanding its fleet to support its National OCS Program.

TransMedics Group, Inc. held its 2024 Annual Meeting of Shareholders on May 23, 2024, where shareholders voted on the election of directors, executive compensation, and the ratification of the company's accounting firm.

TransMedics Group, Inc. announced a 133% increase in revenue and a net income of $12.2 million for the first quarter of 2024, driven by increased utilization of their Organ Care System.

TransMedics Group has finalized the acquisition of its 14th fixed-wing aircraft for approximately $12.5 million, expanding its fleet for the National OCS Program.

TransMedics Group, Inc. announced a 159% increase in both fourth quarter and full year revenue for 2023, alongside a significant rise in transplant volumes.

TransMedics Group has finalized the acquisition of its 13th fixed-wing aircraft for approximately $13.5 million, expanding its fleet for the National OCS Program.

TransMedics Group has finalized the acquisition of its 12th fixed-wing aircraft for approximately $13.1 million, completing a series of related transactions to support its National OCS Program.